Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07050732 · ClinicalTrials.gov registry record · Phase 2

Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons

A Phase 2 study of Respiratory Syncytial Virus (RSV), sponsored by Johns Hopkins University.

Recruiting
Registry status
Phase 2
Development phase
170
Enrollment target
1
Study location

NCT07050732 is a Phase 2 study of Respiratory Syncytial Virus (RSV) that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 170 participants, below the 6,741-participant average among 11 other Respiratory Syncytial Virus (RSV) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07050732, a Phase 2 study of Respiratory Syncytial Virus (RSV), is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
Phase 2
Development phase
170 participants
Enrollment target
1
Study location

Study Summary

This clinical trial is being done to learn more about how well a vaccine (Arexvy®) for respiratory syncytial virus, also known as RSV, works in people with weakened immune systems. The main questions it aims to answer are: * Does 1 or 2 doses of Arexvy work better in people with weakened immune systems? * What medical problems do participants have after receiving Arexvy? Participants with weakened immune systems will: * Receive 3 study vaccines over the course of 1 year * Keep a diary of symptoms for 7 days after each vaccine * Have 3 in-person follow up study visits for checkups and tests over the course of 1.5 years * Have 6 phone follow up study visits over the course of 1.5 years

Conditions Studied

Respiratory Syncytial Virus (RSV)

Interventions

  • OTHER Placebo
  • BIOLOGICAL Arexvy (2 doses total)
  • BIOLOGICAL Arexvy (3 doses total)
  • BIOLOGICAL Arexvy (1 dose total)

Study Locations (1)

Maryland

  • Johns Hopkins University - Baltimore

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2025-12-04
Est. Completion 2028-04
Phase Phase 2

Sponsor

Johns Hopkins University

1,448 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07050732

The ClinicalTrials.gov registry entry for NCT07050732 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,741-participant average among 11 other Respiratory Syncytial Virus (RSV) trials with a reported enrollment target (97% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Respiratory Syncytial Virus (RSV) appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT07050732 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT07050732 about?

NCT07050732 is a clinical study titled "Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons". This clinical trial is being done to learn more about how well a vaccine (Arexvy®) for respiratory syncytial virus, also known as RSV, works in people with weakened immune systems. The main questions it aims to answer are: * Does 1 or 2 doses of Arexvy work better in people with weakened immune sys...

What is the current status of trial NCT07050732?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2025-12-04. Estimated completion is 2028-04.

What conditions does trial NCT07050732 study?

This clinical trial studies the following conditions: Respiratory Syncytial Virus (RSV).

What interventions are being tested in trial NCT07050732?

The interventions under investigation include: Placebo (OTHER), Arexvy (2 doses total) (BIOLOGICAL), Arexvy (3 doses total) (BIOLOGICAL), Arexvy (1 dose total) (BIOLOGICAL).

Who is sponsoring clinical trial NCT07050732?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07050732 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Respiratory Syncytial Virus (RSV)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Respiratory Syncytial Virus (RSV)

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.